The global high-throughput screening (HTS) market size is projected to reach USD 44.5 billion by 2028 from USD 25.7 billion in 2023, at a CAGR of 11.6% during the forecast period. Some of the prominent driving factors of the high throughput screening (HTS) market include robust R&D investments by pharmaceutical & biotechnology companies and the advent of innovative HTS solutions to support the increasing consumer needs around drug discovery & development. Expanding applications of HTS in life sciences markets along with the growing demand in emerging economies offer growth opportunities for market players.
The prominent players in the global high-throughput screening (HTS) market are Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), PerkinElmer, Inc. (US), Tecan Trading AG (Switzerland), AXXAM S.p.A (Italy), Promega Corporation (US), Bio-Rad Laboratories, Inc.(US), Promega Corporation (US), Hamilton Company (US), Corning Incorporated (US), Charles River Laboratories (US), Lonza (Switzerland), REPROCELL Inc. (Japan), Aurora Biomed (Canada), BMG LABTECH (Germany), DIANA Biotechnologies, s.r.o. (Czech Republic), NanoTemper Technologies GmbH (Germany), Creative Biolabs (US), Biomat Srl (Italy), HighRes Biosolutions (US), Cyclica Inc. (Canada), Crown Bioscience (US), and Sygnature Discovery (UK).
To know about the assumptions considered for the study download the pdf brochure
Thermo Fisher Scientific Inc. (US)
Thermo Fisher Scientific Inc. is a dominant player in the high-throughput screening (HTS) market, offering a comprehensive range of products and solutions that position them for success. They provide cutting-edge technologies for automated liquid handling, high-content screening, real-time PCR, and microplate readers, enabling scientists to process large volumes of samples and data rapidly. Furthermore, Thermo Fisher Scientific's commitment to innovation, quality, and customer support, along with their global reach and industry expertise, positions them as a leading choice for HTS solutions, offering researchers the tools they need to accelerate drug discovery, molecular biology, genomics, and other applications in the HTS field.
Agilent Technologies, Inc (US)
Agilent's strength lies in their highly configurable and flexible HTS solutions, allowing customers to tailor their systems to specific needs and optimize workflows. Their expertise in assay development and optimization further sets them apart, providing valuable assistance to customers in achieving optimal performance and meaningful results. Agilent's commitment to superior data quality and accuracy, supported by advanced analytical capabilities and robust instrumentation, further establishes their competitive advantage. Furthermore, Agilent's strategic focus on technology leadership enables them to introduce innovative HTS products through continuous research and development. These factors combined with their reputation for quality and customer support position Agilent as a trusted and preferred partner in the HTS market.
Merck KGaA (Germany)
Merck KGaA has a strong right to win in the HTS market due to its strong product portfolio, competitive pricing, global reach, and strong customer relationships. The company's HTS products and services are used by pharmaceutical companies, academic research institutions, and government agencies to accelerate the drug discovery process. Merck's HTS products and services are good value for customers and are well-positioned to continue to grow in the HTS market.
High-Throughput Screening (HTS) Market by Product (Instrument, Consumable, Service), Technology (Cell-based Assays, Lab-on-a-Chip, Label-free), Application (Drug Discovery, Life Sciences Research), End User (Pharma, Biotech, CRO) - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE